Hantz Financial Services Inc. Acquires 1,061 Shares of HealthEquity, Inc. $HQY

Hantz Financial Services Inc. grew its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 2,587.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,102 shares of the company’s stock after buying an additional 1,061 shares during the period. Hantz Financial Services Inc.’s holdings in HealthEquity were worth $115,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Invesco Ltd. boosted its holdings in shares of HealthEquity by 50.6% during the 1st quarter. Invesco Ltd. now owns 2,446,198 shares of the company’s stock valued at $216,171,000 after buying an additional 821,425 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of HealthEquity by 1.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,133,166 shares of the company’s stock valued at $100,138,000 after buying an additional 15,458 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of HealthEquity by 1.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,100,970 shares of the company’s stock valued at $97,293,000 after buying an additional 14,159 shares in the last quarter. Stephens Investment Management Group LLC boosted its holdings in shares of HealthEquity by 1.8% during the 1st quarter. Stephens Investment Management Group LLC now owns 1,069,446 shares of the company’s stock valued at $94,507,000 after buying an additional 19,009 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of HealthEquity by 24.9% during the 1st quarter. Wellington Management Group LLP now owns 848,940 shares of the company’s stock valued at $75,021,000 after buying an additional 169,337 shares in the last quarter. Institutional investors own 99.55% of the company’s stock.

Insider Transactions at HealthEquity

In other HealthEquity news, EVP Michael Henry Fiore sold 1,781 shares of the business’s stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $88.21, for a total value of $157,102.01. Following the completion of the transaction, the executive vice president owned 49,795 shares of the company’s stock, valued at approximately $4,392,416.95. The trade was a 3.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Delano Ladd sold 6,000 shares of the business’s stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $94.11, for a total value of $564,660.00. Following the completion of the transaction, the executive vice president directly owned 79,456 shares of the company’s stock, valued at approximately $7,477,604.16. This trade represents a 7.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 9,281 shares of company stock valued at $859,867. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

HQY has been the topic of a number of research reports. KeyCorp dropped their target price on shares of HealthEquity from $125.00 to $120.00 and set an “overweight” rating on the stock in a report on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price target on HealthEquity from $125.00 to $126.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 3rd. Jefferies Financial Group lifted their price target on HealthEquity from $130.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Raymond James Financial restated a “strong-buy” rating and set a $120.00 price objective (up from $115.00) on shares of HealthEquity in a research note on Tuesday, July 8th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of HealthEquity in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $121.31.

HealthEquity Price Performance

Shares of NASDAQ:HQY opened at $94.81 on Tuesday. HealthEquity, Inc. has a fifty-two week low of $74.07 and a fifty-two week high of $116.65. The business has a 50-day simple moving average of $92.83 and a two-hundred day simple moving average of $95.26. The company has a debt-to-equity ratio of 0.47, a quick ratio of 4.23 and a current ratio of 4.23. The firm has a market cap of $8.17 billion, a price-to-earnings ratio of 57.46, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Tuesday, September 2nd. The company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. HealthEquity had a return on equity of 12.04% and a net margin of 11.49%.The business had revenue of $325.80 million during the quarter, compared to analyst estimates of $320.68 million. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. On average, analysts expect that HealthEquity, Inc. will post 2.32 earnings per share for the current year.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.